11,298 Boston Scientific Corporation $BSX Shares Acquired by Kintegral Advisory LLC

Kintegral Advisory LLC lifted its holdings in Boston Scientific Corporation (NYSE:BSX) by 21.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 63,075 shares of the medical equipment provider’s stock after acquiring an additional 11,298 shares during the quarter. Kintegral Advisory LLC’s holdings in Boston Scientific were worth $2,753,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in BSX. Clal Insurance Enterprises Holdings Ltd purchased a new stake in shares of Boston Scientific in the first quarter worth about $28,000. Cassaday & Co Wealth Management LLC purchased a new position in Boston Scientific during the first quarter valued at approximately $32,000. Measured Wealth Private Client Group LLC raised its position in Boston Scientific by 244.9% during the first quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 387 shares in the last quarter. Kelleher Financial Advisors acquired a new position in Boston Scientific in the second quarter valued at approximately $25,000. Finally, Nvwm LLC lifted its holdings in Boston Scientific by 526.2% in the third quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 542 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the topic of a number of analyst reports. Argus reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Friday, July 31st. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Royal Bank Of Canada lowered their price target on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, July 30th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $60.00 price target (down from $75.00) on shares of Boston Scientific in a research report on Thursday, July 30th. Finally, Piper Sandler dropped their price target on shares of Boston Scientific from $65.00 to $60.00 in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $68.23.

Insider Buying and Selling

In related news, CEO Michael F. Mahoney bought 186,240 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edward J. Ludwig bought 5,000 shares of the company’s stock in a transaction dated Friday, July 31st. The stock was bought at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders purchased 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is owned by corporate insiders.

Boston Scientific Price Performance

BSX traded up $0.20 during trading on Friday, hitting $44.34. The company’s stock had a trading volume of 12,409,619 shares, compared to its average volume of 17,698,992. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a twelve month low of $41.38 and a twelve month high of $105.65. The business’s fifty day simple moving average is $46.06 and its 200 day simple moving average is $49.76. The firm has a market capitalization of $64.26 billion, a price-to-earnings ratio of 17.95, a P/E/G ratio of 1.07 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the prior year, the company posted $0.75 EPS. The business’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 3.24 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.